Bicycle therapeutics announces settlement of patent dispute with pepscan systems b.v.

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq:bcyc), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that it has entered into a settlement and license agreement with pepscan systems b.v. regarding bicycle's use of pepscan's clips peptide technology. the companies have agreed to settle all intellectual property disputes worldwide. unde
BCYC Ratings Summary
BCYC Quant Ranking